{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee KL"],"funding":["Lottery Health New Zealand","Maurice Wilkins Centre for Molecular BioDiscovery","Ministry of Business, Innovation and Employment","Health Research Council of New Zealand"],"pagination":["14-22"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8632304"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["Pancreatic islet-cell function and volume are both key determinants of the maintenance of metabolic health. Insulin resistance and islet-cell dysfunction often occur in the earlier stages of type 2 diabetes (T2D) progression. The ability of the islet cells to respond to insulin resistance by increasing hormone output accompanied by increased islet-cell volume is key to maintaining blood glucose control and preventing further disease progression. Eventual β-cell loss is the main driver of full-blown T2D and insulin-dependency. Researchers are targeting T2D with approaches that include those aimed at enhancing the function of the patient's existing β-cell population, or replacing islet β-cells. Another approach is to look for agents that enhance the natural capacity of the β-cell population "],"journal":["Islets"],"pubmed_title":["Vesiculin derived from IGF-II drives increased islet cell mass in a mouse model of pre-diabetes."],"pmcid":["PMC8632304"],"funding_grant_id":["03/190","3626585","UOAX9902; PMIX0201; UOAX0815","3602434"],"pubmed_authors":["Li X","Montgomery K","Aitken JF","Williams GM","Cooper GJS","Lee KL","Brimble MA","Hsu HL"],"additional_accession":[]},"is_claimable":false,"name":"Vesiculin derived from IGF-II drives increased islet cell mass in a mouse model of pre-diabetes.","description":"Pancreatic islet-cell function and volume are both key determinants of the maintenance of metabolic health. Insulin resistance and islet-cell dysfunction often occur in the earlier stages of type 2 diabetes (T2D) progression. The ability of the islet cells to respond to insulin resistance by increasing hormone output accompanied by increased islet-cell volume is key to maintaining blood glucose control and preventing further disease progression. Eventual β-cell loss is the main driver of full-blown T2D and insulin-dependency. Researchers are targeting T2D with approaches that include those aimed at enhancing the function of the patient's existing β-cell population, or replacing islet β-cells. Another approach is to look for agents that enhance the natural capacity of the β-cell population ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-26T16:04:43.623Z","creation":"2022-02-11T13:59:51.326Z"},"accession":"S-EPMC8632304","cross_references":{"pubmed":["34632959"],"doi":["10.1080/19382014.2021.1982326"]}}